ALKERMES PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.68 USD | +0.98% |
|
+3.48% | -11.03% |
| 04-09 | Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday | MT |
| 04-09 | Alkermes Says Potential Narcolepsy Drug Improves Wakefulness in Phase 1b Study | MT |
| Sales 2024 * | 1.52B 122B | Sales 2025 * | 1.52B 122B | Capitalization | 4.18B 334B |
|---|---|---|---|---|---|
| Net income 2024 * | 352M 28.18B | Net income 2025 * | 331M 26.5B | EV / Sales 2024 * | 2.23 x |
| Net cash position 2024 * | 791M 63.3B | Net cash position 2025 * | 1.17B 93.7B | EV / Sales 2025 * | 1.97 x |
| P/E ratio 2024 * |
12.1
x | P/E ratio 2025 * |
13.4
x | Employees | 2,100 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.59% |
More Fundamentals
* Assessed data
More news
Latest transcript on Alkermes plc
More recommendations
More press releases
| 1 day | +0.98% | ||
| 1 week | +3.48% | ||
| Current month | -8.83% | ||
| 1 month | -7.84% | ||
| 3 months | -11.03% | ||
| 6 months | -0.08% | ||
| Current year | -11.03% |
1 week
23.76
24.81
1 month
23.4827.56
Current year
23.4832.88
1 year
22.0133.71
3 years
21.1733.71
5 years
11.9833.71
10 years
11.9880.71
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Pops
CEO | Chief Executive Officer | 62 | 31/01/91 |
Blair Jackson
DFI | Director of Finance/CFO | 51 | 31/12/98 |
Shane Cooke
PSD | President | 61 | 31/08/11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Pops
CEO | Chief Executive Officer | 62 | 31/01/91 |
Nancy Snyderman
BRD | Director/Board Member | 72 | 25/05/16 |
Brian McKeon
BRD | Director/Board Member | 61 | 09/12/20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 15.32% | 215 M€ | +10.68% | - | |
| 2.65% | 1 M€ | -5.79% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 24.68 | +0.98% | 1,016,741 |
| 25/04/24 | 24.44 | -0.85% | 1,313,771 |
| 24/04/24 | 24.65 | +1.61% | 1,737,019 |
| 23/04/24 | 24.26 | +0.79% | 1,245,764 |
| 22/04/24 | 24.07 | +0.92% | 1,708,265 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Calendar
01/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
24.68
USD
Average target price
35.25
USD
Spread / Average Target
+42.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.03% | 4.18B | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ALKS Stock
